Is SMMT or IMNM more profitable?

Immunome's return on equity of -51.15% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Immunome N/A -51.15% -47.32%

Does the media prefer SMMT or IMNM?

In the previous week, Summit Therapeutics had 2 more articles in the media than Immunome. MarketBeat recorded 6 mentions for Summit Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Summit Therapeutics' score of 0.80 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, IMNM or CYTK?

Immunome has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $4.02M 706.01 -$212.39M -$2.38 N/A Cytokinetics $67.67M 141.15 -$784.96M -$7.22 N/A

Is IMNM or CYTK more profitable?

Immunome has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Cytokinetics -1,321.12% N/A -56.07%

Does the media prefer IMNM or CYTK?

In the previous week, Cytokinetics had 15 more articles in the media than Immunome. MarketBeat recorded 19 mentions for Cytokinetics and 4 mentions for Immunome. Cytokinetics' average media sentiment score of 0.93 beat Immunome's score of 0.83 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IMNM or NUVL?

Immunome has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $4.02M 706.01 -$212.39M -$2.38 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is IMNM or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Nuvalent N/A -40.11% -35.43%

Do analysts rate IMNM or RDY?

Immunome currently has a consensus price target of $34.18, indicating a potential upside of 36.56%. Given Immunome's stronger consensus rating and higher probable upside, research analysts clearly believe Immunome is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.85 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to IMNM or RDY?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Immunome. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Immunome's score of 0.83 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KYMR or IMNM?

In the previous week, Kymera Therapeutics had 23 more articles in the media than Immunome. MarketBeat recorded 27 mentions for Kymera Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Kymera Therapeutics' score of -0.13 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunome (IMNM) Competitors

$25.03 -0.79 (-3.06%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$24.97 -0.06 (-0.24%)

As of 08/7/2026 07:44 PM Eastern

Compare

IMNM vs. SMMT, CYTK, NUVL, RDY, and KYMR

Should you buy Immunome stock or one of its competitors? MarketBeat compares Immunome with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunome include Summit Therapeutics (SMMT), Cytokinetics (CYTK), Nuvalent (NUVL), Dr. Reddy's Laboratories (RDY), and Kymera Therapeutics (KYMR).

How does Immunome compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, Summit Therapeutics had 2 more articles in the media than Immunome. MarketBeat recorded 6 mentions for Summit Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Summit Therapeutics' score of 0.80 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summit Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, Immunome has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summit Therapeutics presently has a consensus target price of $26.15, indicating a potential upside of 87.35%. Immunome has a consensus target price of $34.18, indicating a potential upside of 36.56%. Given Summit Therapeutics' higher possible upside, equities analysts plainly believe Summit Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Immunome's return on equity of -51.15% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Immunome	N/A	-51.15%	-47.32%

Immunome has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Immunome	$4.02M	706.01	-$212.39M	-$2.38	N/A

Summary

Immunome beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Immunome compare to Cytokinetics?

Immunome (NASDAQ:IMNM) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Immunome has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Cytokinetics	-1,321.12%	N/A	-56.07%

In the previous week, Cytokinetics had 15 more articles in the media than Immunome. MarketBeat recorded 19 mentions for Cytokinetics and 4 mentions for Immunome. Cytokinetics' average media sentiment score of 0.93 beat Immunome's score of 0.83 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immunome presently has a consensus price target of $34.18, indicating a potential upside of 36.56%. Cytokinetics has a consensus price target of $100.85, indicating a potential upside of 31.38%. Given Immunome's higher possible upside, equities analysts plainly believe Immunome is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Immunome has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Immunome has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$4.02M	706.01	-$212.39M	-$2.38	N/A
Cytokinetics	$67.67M	141.15	-$784.96M	-$7.22	N/A

Summary

Immunome beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Immunome compare to Nuvalent?

Immunome (NASDAQ:IMNM) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immunome has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$4.02M	706.01	-$212.39M	-$2.38	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Immunome currently has a consensus target price of $34.18, indicating a potential upside of 36.56%. Nuvalent has a consensus target price of $127.73, indicating a potential upside of 3.04%. Given Immunome's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunome is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Nuvalent's return on equity of -40.11% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Nuvalent	N/A	-40.11%	-35.43%

Immunome has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

In the previous week, Immunome had 4 more articles in the media than Nuvalent. MarketBeat recorded 4 mentions for Immunome and 0 mentions for Nuvalent. Immunome's average media sentiment score of 0.83 beat Nuvalent's score of 0.00 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Positive
Nuvalent	Neutral

Summary

Immunome beats Nuvalent on 11 of the 14 factors compared between the two stocks.

How does Immunome compare to Dr. Reddy's Laboratories?

Immunome (NASDAQ:IMNM) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Immunome currently has a consensus price target of $34.18, indicating a potential upside of 36.56%. Given Immunome's stronger consensus rating and higher probable upside, research analysts clearly believe Immunome is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$4.02M	706.01	-$212.39M	-$2.38	N/A
Dr. Reddy's Laboratories	$331.19B	0.03	$456M	$0.44	27.76

44.6% of Immunome shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunome has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Immunome's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Immunome. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Immunome's score of 0.83 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dr. Reddy's Laboratories beats Immunome on 9 of the 16 factors compared between the two stocks.

How does Immunome compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Immunome (NASDAQ:IMNM) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Immunome has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.82% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.82%	-19.66%
Immunome	N/A	-51.15%	-47.32%

44.6% of Immunome shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Kymera Therapeutics had 23 more articles in the media than Immunome. MarketBeat recorded 27 mentions for Kymera Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Kymera Therapeutics' score of -0.13 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$105M	85.15	-$311.35M	-$3.24	N/A
Immunome	$4.02M	706.01	-$212.39M	-$2.38	N/A

Kymera Therapeutics presently has a consensus target price of $125.65, indicating a potential upside of 16.86%. Immunome has a consensus target price of $34.18, indicating a potential upside of 36.56%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Immunome has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

Summary

Immunome beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.83B	$3.69B	$7.02B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-10.52	9.02	271.11	25.19
Price / Sales	706.01	1,269.90	590.84	78.19
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	4.35	18.10	13.25	6.22
Net Income	-$212.39M	-$13.25M	$3.45B	$342.66M
7 Day Performance	9.97%	6.24%	4.67%	4.41%
1 Month Performance	3.60%	-3.50%	-1.28%	-1.10%
1 Year Performance	158.31%	61.28%	77.33%	23.99%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	3.2364 of 5 stars	$25.03 -3.1%	$34.18 +36.6%	+158.3%	$2.83B	$4.02M	N/A	40	Upcoming Earnings Insider Trade
SMMT Summit Therapeutics	3.923 of 5 stars	$12.73 -2.9%	$26.15 +105.5%	-51.3%	$10.26B	N/A	N/A	110	Analyst Forecast
CYTK Cytokinetics	3.5377 of 5 stars	$80.17 -0.6%	$99.90 +24.6%	+125.0%	$9.99B	$105.82M	N/A	250	Trending News Earnings Report Analyst Forecast
NUVL Nuvalent	1.8478 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40
RDY Dr. Reddy's Laboratories	2.8323 of 5 stars	$11.75 -0.2%	N/A	-11.6%	$9.74B	$331.19B	26.52	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. SMMT, CYTK, NUVL, RDY, and KYMR

How does Immunome compare to Summit Therapeutics?

Summary

How does Immunome compare to Cytokinetics?

Summary

How does Immunome compare to Nuvalent?

Summary

How does Immunome compare to Dr. Reddy's Laboratories?

Summary

How does Immunome compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. SMMT, CYTK, NUVL, RDY, and KYMR

How does Immunome compare to Summit Therapeutics?

Does the media prefer SMMT or IMNM?

Do insiders and institutionals believe in SMMT or IMNM?

Which has more risk & volatility, SMMT or IMNM?

Do analysts prefer SMMT or IMNM?

Is SMMT or IMNM more profitable?

Which has preferable valuation & earnings, SMMT or IMNM?

Summary

How does Immunome compare to Cytokinetics?

Is IMNM or CYTK more profitable?

Does the media prefer IMNM or CYTK?

Do insiders & institutionals believe in IMNM or CYTK?

Do analysts recommend IMNM or CYTK?

Which has more risk & volatility, IMNM or CYTK?

Which has preferable earnings & valuation, IMNM or CYTK?

Summary

How does Immunome compare to Nuvalent?

Do institutionals and insiders believe in IMNM or NUVL?

Which has higher valuation and earnings, IMNM or NUVL?

Do analysts prefer IMNM or NUVL?

Is IMNM or NUVL more profitable?

Which has more risk & volatility, IMNM or NUVL?

Does the media favor IMNM or NUVL?

Summary

How does Immunome compare to Dr. Reddy's Laboratories?

Do analysts rate IMNM or RDY?

Which has stronger earnings and valuation, IMNM or RDY?

Do institutionals & insiders believe in IMNM or RDY?

Which has more volatility and risk, IMNM or RDY?

Is IMNM or RDY more profitable?

Does the media refer more to IMNM or RDY?

Summary

How does Immunome compare to Kymera Therapeutics?

Is KYMR or IMNM more profitable?

Do insiders & institutionals have more ownership in KYMR or IMNM?

Does the media prefer KYMR or IMNM?

Which has higher earnings and valuation, KYMR or IMNM?

Do analysts prefer KYMR or IMNM?

Which has more volatility and risk, KYMR or IMNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools